8 results about "Mannosamine" patented technology

The invention discloses an enzymatic cascade nanogel system targeting Lawsonia intracellularis and a preparation method of the enzymatic cascade nanogel system. The enzymatic cascade nanogel system comprises the following components: 0.05-2% of sodium alginate; 0.02 to 0.3 percent of calcium chloride; 2 to 6 percent of N, O-carboxymethyl chitosan; 0.2 to 1% of D-mannosamine hydrochloride; 0.05 to 0.2 percent of tilmicosin; 0.0005 to 0.002 percent of cerium dioxide nano enzyme; and 0.0005 to 0.002 percent of glucose oxidase. The enzymatic cascade nanogel system provided by the invention has a dual gel structure of a dynamic covalent bond core and an ionic bond shell, and can realize targeted programmed release of tilmicosin; the endocytosis of host cells on the enzymatic cascade nanogel system is actively enhanced, the intracellular transport capacity of tilmicosin is improved, and the intracellular drug concentration is improved; glucose oxidase consumes glucose to generate gluconic acid and H2O2 so as to realize'hunger therapy 'on Lawsonia intracellularis; h2O2 generated by decomposing glucose oxidase by cerium dioxide nano-enzyme generates high-concentration oxygen at an infected part, so that the living environment of the intracellular Lawsonia is deteriorated.

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

Provided is a recombinant Corynebacterium glutamicum, which is genetically engineered to introduce an N-acetyl-mannosamine (ManNAc) synthetic pathway, and is genetically engineered to express a heterologous N-acetylneuraminic acid synthase, a heterologous CMP-N-acetylneuraminic acid synthase, a heterologous lactose transporter, and a heterologous sialyltransferase. Provided is a method for using the recombinant Corynebacterium glutamicum to produce sialyllactose.

The invention discloses a preparation method of an ROS response microsphere encapsulated mitochondrial targeted nootkatone loaded Mxene multifunctional composite material, and relates to the technical field of biomedicine.The preparation method comprises the steps that carboxylated Mxene nanosheets are prepared and dissolved in dimethyl sulfoxide to obtain a product MXene-COOH-NK, then the product MXene-COOH-NK is dissolved in a 2-morpholine ethanesulfonic acid MES solution to obtain a product MXene-COOH-NK-Man, and the MXene-COOH-NK-Man is loaded on the Mxene multifunctional composite material to obtain the ROS response microsphere encapsulated mitochondrial targeted nootkatone loaded Mxene multifunctional composite material. On the basis, the ROS response microsphere encapsulated mitochondrial targeted Mxene loaded nootkatone is prepared. MXene has near-infrared photothermal conversion performance and supports light controlled drug release and local mild thermal therapy, MXene-COOH at NK can directly enrich chondrocyte mitochondria after being modified by mannosamine, expression of inflammatory factors is further inhibited, boric acid ester bonds are contained in the microspheres, and the MXene-COOH at NK can be used for preparing a drug for treating chondrocyte mitochondria, so that the MXene-COOH at NK can be used for preparing a drug for treating chondrocyte mitochondria. The nootkatone is broken under the high ROS environment condition of an OA focus, fixed-point and on-demand release of the medicine nootkatone is achieved, and whole body exposure is reduced.

The invention provides a UDP-N-acetylmannosamine epimerase mutant as well as a recombinant strain and application of the UDP-N-acetylmannosamine epimerase mutant. Compared with a wild type, the UDP-N-acetylmannosamine epimerase mutant disclosed by the invention has higher enzyme activity, can be used for efficiently preparing N-acetylneuraminic acid, and has the potential of industrial application.

This invention proposes a method for separating biosulfur, comprising: (1) adding an organic flocculant to a mixing tank containing a biosulfurization solution and stirring to obtain a mixed solution; wherein the organic flocculant is selected from at least one of galactosamine, N-acetylglucosamine, and mannosamine; (2) transferring the mixed solution to a settling tank and allowing it to stand to form a supernatant and a bottom precipitate; and (3) separating the supernatant and the bottom precipitate in the settling tank. The method of this invention can achieve efficient separation of biosulfur, with a biosulfur flocculation rate of 95–99 wt%. This invention also provides the application of at least one of galactosamine, N-acetylglucosamine, and mannosamine in the separation of biosulfur.

The invention relates to an antibacterial glycopeptide and application thereof in treating intervertebral space infection. The glycopeptide has a structure as shown in a formula I, in the formula I, Bip represents a 4-biphenylacetic acid fragment, FF represents a dipeptide linker of two phenylalanine, X represents a cationic antibacterial peptide fragment of 6-8 amino acids, ManN represents a mannosamine fragment, Bip and FF are connected through an amido bond, the C end of FF is connected to the N end of X, and X and ManN are connected through an amido bond. The antibacterial glycopeptides of the present application can be used for the treatment of intractable infections, especially intervertebral space infections. The invention relates to Bip-FF-X-ManNI.

The invention provides optimized upstream processes for the production of recombinant gonadotropins including corifollitropin alfa (CFA), recombinant human chorionic gonadotropin (r-hCG), and recombinant human follicle- stimulating hormone (r-hFSH) in mammalian cell culture. The processes comprise revival of CHO cells from cryopreservation, expansion in shake flasks, seed generation in wave bioreactors, and production in stirred-tank bioreactors operated in fed-batch mode. Defined media supplemented with additives such as N-acetyl mannosamine, or stabilized glutamine enhance cell viability, productivity, and glycosylation quality. Cultures are terminated at defined viability thresholds or timepoints, and clarified by sequential depth and membrane filtration. The methods offer scalability, reproducibility, and superior product quality compared to conventional approaches, enabling consistent large-scale manufacture of therapeutic gonadotropins for fertility treatments and hormone therapies.